Or Yat Sun 4

What Happened Or Yat Sun, Chief Scientific Officer of Enanta Pharmaceuticals (ENTA), received equity awards that settled into 6,875 shares of Enanta common stock on February 12, 2026 (two separate awards: 1,650 and 5,225 shares). To cover tax withholding obligations, 3,413 of those shares were automatically forfeited at $14.25 per share (total value withheld = $48,635). The awards were issued at no cash cost to the reporting person (grant price $0.00), leaving a net 3,462 shares delivered to the insider.

Key Details

• Transaction date: February 12, 2026 (filed February 13, 2026) — appears timely.
• Grants: 1,650 shares (PSUs) and 5,225 shares (rTSRU) acquired at $0.00.
• Tax withholding: 3,413 shares surrendered at $14.25/share for $48,635 (coded F).
• Net shares received by insider: 3,462 shares (6,875 granted − 3,413 withheld).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnotes: PSUs vested based on two-year R&D milestones (F1); rTSRU vested based on relative total shareholder return vs. Nasdaq Biotech Index (F2); F3 notes the automatic forfeiture to cover withholding taxes.

Context

• PSUs and rTSRUs are performance-based awards that convert to stock when performance conditions are met; these grants are not open-market purchases or sales by the insider.
• The withholding of shares to pay taxes is a routine administrative step and does not necessarily indicate a buy or sell signal.
• This filing reports issuance and tax withholding only; there was no open-market sale or exercise-for-cash reported on this date.